Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials
BMJ · 18.06.2025 · 389 · e082007
DOI: 10.1136/bmj-2024-082007 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift BMJ, online erschienen am 18.06.2025. Verfasst von Zhila Semnani-Azad und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA. Hauptthemen laut MEDLINE: Body Weight, Caloric Restriction, Cardiometabolic Risk Factors, Diet, Reducing. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Objective
To assess the effect of intermittent fasting diets, with continuous energy restriction or unrestricted (ad-libitum) diets on intermediate cardiometabolic outcomes from randomised clinical trials.
Design
Systematic review and network meta-analysis. Data sources Medline, Embase, and central databases from inception to 14 November 2024. Eligibility criteria for selecting studies Randomised clinical trials comparing the association of intermittent fasting diets (alternate day fasting, time restricted eating, and whole day fasting), continuous energy restriction, and ad-libitum diets were included. Main outcomes Outcomes included body weight (primary) and measures of anthropometry, glucose metabolism, lipid profiles, blood pressure, C-reactive protein, and markers of liver disease. Data synthesis A network meta-analysis based on a frequentist framework was performed with data expressed as mean difference with 95% confidence intervals (CIs). The certainty of the evidence was assessed using grading of recommendations assessment, development, and evaluation (GRADE).
Results
99 randomised clinical trials involving 6582 adults of varying health conditions (720 healthy, 5862 existing health conditions) were identified. All intermittent fasting and continuous energy restriction diet strategies reduced body weight when compared with ad-libitum diet. Compared with continuous energy restriction, alternate day fasting was the only form of intermittent fasting diet strategy to show benefit in body weight reduction (mean difference −1.29 kg (95% CI −1.99 to −0.59), moderate certainty of evidence). Additionally, alternate day fasting showed a trivial reduction in body weight compared with both time restricted eating and whole day fasting (mean difference −1.69 kg (−2.49 to −0.88) and −1.05 kg (−1.90 to −0.19), respectively, both with moderate certainty of evidence). Estimates were similar among trials with less than 24 weeks follow-up (n=76); however, moderate-to-long-term trials (≥24 weeks, n=17) only showed benefits in weight reduction in diet strategies compared with ad-libitum. Furthermore, in comparisons between intermittent fasting strategies, alternate day fasting lowered total cholesterol, triglycerides, and non-high density lipoprotein compared with time restricted eating. Compared with whole day fasting, however, time restricted eating resulted in a small increase in total cholesterol, low density lipoprotein cholesterol, and non-high density lipoprotein cholesterol. No differences were noted between intermittent fasting, continuous energy restriction, and ad-libitum diets for HbA 1c and high density lipoprotein.
Conclusions
Minor differences were noted between some intermittent fasting diets and continuous energy restriction, with some benefit of weight loss with alternate day fasting in shorter duration trials. The current evidence provides some indication that intermittent fasting diets have similar benefits to continuous energy restriction for weight loss and cardiometabolic risk factors. Longer duration trials are needed to further substantiate these findings.
Trial registration
ClinicalTrials.gov NCT05309057 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA.
- Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Charité Universitätsmedizin, Berlin, Germany.
- German Center for Diabetes Research, Neuherberg, Germany.
ORCID-Profile: John L Sievenpiper
Förderung
- NIDDK NIH HHS
Zitieren
APA
Semnani-Azad, Z., Khan, T. A., Chiavaroli, L., Chen, V., Bhatt, H. A., Chen, A., Chiang, N., Oguntala, J., Kabisch, S., Lau, D. C., Wharton, S., Sharma, A. M., Harris, L., Leiter, L. A., Hill, J. O., Hu, F. B., Lean, M. E., Kahleová, H., Rahelic, D., …, & Sievenpiper, J. L. (2025). Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ, 389, e082007. https://doi.org/10.1136/bmj-2024-082007
Vancouver
Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025;389:e082007. doi:10.1136/bmj-2024-082007
BibTeX
@article{SemnaniAzad2025,
author = {Semnani-Azad, Zhila and Khan, Tauseef A and Chiavaroli, Laura and Chen, Victoria and Bhatt, Hardil Anup and Chen, Alisia and Chiang, Nicholas and Oguntala, Julianah and Kabisch, Stefan and Lau, David Cw and Wharton, Sean and Sharma, Arya M and Harris, Leanne and Leiter, Lawrence A and Hill, James O and Hu, Frank B and Lean, Michael Ej and Kahleová, Hana and Rahelic, Dario and Salas-Salvadó, Jordi and Kendall, Cyril Wc and Sievenpiper, John L},
title = {Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials},
journal = {BMJ},
year = {2025},
volume = {389},
pages = {e082007},
doi = {10.1136/bmj-2024-082007}
}
EUVIMED